Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FTC blockage of Amgen's US$28 BLN takeover of Horizon

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 16, 2023 11:39am

146 Views

Post# 35450412

RE:RE:FTC blockage of Amgen's US$28 BLN takeover of Horizon

William Blair analyst Matt Phipps, Ph.D argues that Amgen desperately needs those additional assets to drive revenue growth given how its existing portfolio has struggled.

William Blair's Phipps arguement supports the long standing observation that Big Pharma is faced with a looming patent cliff and needs to fill its pipeline with new product assets to drive revenue growth.

ONCY is well positioned as an acqusition target for Big Pharma as a "bolt-on" asset that will help fill their current pipeline and revenue growth challenges.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario